Abstracts tagged "Abatacept and health care cost"

Abstract Number: 1125 • 2019 ACR/ARP Annual Meeting
Health Care Resource Utilization and Costs in Patients with Juvenile Idiopathic Arthritis Treated with Abatacept and Other Targeted Disease Modifying Anti-rheumatic Drugs
Joe Zhuo¹, Ying Bao ², Qian Xia ², Aarti Rao ³, Niyati Sharma ³, Xue Han ⁴ and Robert Wong ⁵, ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Lawrenceville, NJ, ³Mu Sigma, Bangalore, India, ⁴Bristol-Myers Squibb Company, Princeton, NJ, ⁵Bristol-Myers Squibb, Princeton
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a common, chronic rheumatic disease of childhood that carries substantial economic impact on patients (pts) and families1. The objective…
Abstract Number: 95 • 2014 ACR/ARHP Annual Meeting
Comparison of Patient Characteristics, Healthcare Costs, and Biologic Persistence Between Patients with Rheumatoid Arthritis Initiating First- or Second-Line Subcutaneous Abatacept, Adalimumab, or Etanercept
S Johnston¹, F Lobo², D McMorrow¹, R Fowler¹, D Smith¹ and A Nadkarni², ¹Truven Health Analytics, Bethesda, MD, ²Bristol-Myers Squibb, Plainsboro, NJ
Background/Purpose: There are currently very limited comparative published data on the characteristics, healthcare costs, and biologic persistence among patients with RA who have been treated…